Praluent and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Praluent (alirocumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Lipitor, and have Hyperlipidaemia.

The phase IV clinical study analyzes which people have Hearing loss when taking Praluent. It is created by eHealthMe based on reports of 24,843 people who have side effects when taking Praluent from the FDA, and is updated regularly.

What is Praluent?

Praluent has active ingredients of alirocumab. It is often used in high blood cholesterol. eHealthMe is studying from 24,963 Praluent users. Check the latest studies of Praluent.

What is Hearing loss?

Hearing loss is found to be associated with 1,351 drugs and 2,377 conditions by eHealthMe. Check the latest studies of Hearing loss.

On May, 07, 2026

24,843 people reported to have side effects when taking Praluent.
Among them, 22 people (0.09%) have Hearing loss.

Among these 22 people:

How long have people been on Praluent when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Praluent? *

female: 40.91 %
male: 59.09 %

What is the age of people who have Hearing loss when taking Praluent? *

What are other drugs people take besides Praluent? *

What are other side effects people have besides Hearing loss? *

Rashes (redness): 4 people, 18.18%
Nasopharyngitis (inflammation of the nasopharynx): 3 people, 13.64%
Dizziness: 3 people, 13.64%
Hallucinations (sensations that appear real but are created by your mind): 3 people, 13.64%
Insomnia (sleeplessness): 3 people, 13.64%
Weakness: 2 people, 9.09%
Blindness: 2 people, 9.09%
Headache (pain in head): 2 people, 9.09%
Hypoaesthesia (reduced sense of touch or sensation): 2 people, 9.09%
Injection Site Swelling: 2 people, 9.09%

What are the existing conditions these people have? *

Hyperlipidaemia (presence of excess lipids in the blood): 6 people, 27.27%
Low Density Lipoprotein Increased (cholesterol increased in blood): 3 people, 13.64%
Heart Attack: 2 people, 9.09%
Chest Pain: 2 people, 9.09%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 4.55%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.55%
Heart Disease: 1 person, 4.55%
Enlarged Prostate: 1 person, 4.55%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Praluent and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Praluent:

Praluent (24,963 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Praluent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,351 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,377 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on alirocumab (the active ingredients of Praluent) and Praluent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.